What we're reading, April 1, 2016: Federal Trade Commission files lawsuit to stop pay-to-delay deals; CMS' bundled payment initiative for joint replacement takes effect; and scientists confirm link between Zika virus and microcephaly.
The US Federal Trade Commission has filed a lawsuit to stop pay-to-delay deals for generic drugs. The agency going after 4 drug makers for allegedly paying generic rivals to delay the launch of painkillers, and this is the first lawsuit that argues the deal thwarted competition, according to STAT. The legality of these deals is not concrete. The Supreme Court ruled these deals may be subject to antitrust review, but whether cash is the only questionable deal was left open to interpretation.
Today, CMS’ bundled-payment initiative for hip and knee replacement takes effect for nearly 800 hospitals in 67 metropolitan areas. These chosen hospitals will now be held accountable for all costs related to hip and knee replacement for 90 days, reported The Wall Street Journal. CMS is estimating that the program will save $343 million over the next 5 years. Hospitals have a target price to meet and if payments are less than the target, CMS will pay the hospital the difference. However, in the second year of the program, hospitals with payments exceeding the target will owe CMS the difference.
As top US health officials gather in Atlanta to address the possibility of local transmission of the Zika virus, the World Health Organization announced that a connection between the virus and microcephaly has been found. Scientists confirmed the link and that Zika is linked to the condition in which babies are born with small heads and brain damage, according to NPR.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More